Glibenclamide And Cariovascular Risk In Diabetic Patients

Glibenclamide (also known as glyburide) is an oral medication used to treat type 2 diabetes. It belongs to a class of drugs called sulfonylureas, which work by stimulating the pancreas to release more insulin, thereby lowering blood glucose levels

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2024-12-17
DOI
https://doi.org/10.5281/zenodo.14505562
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Glibenclamide And Cariovascular Risk In Diabetic Patients

Zenodo (CERN European Organization for Nuclear Research)
Diabetes Treatment and Management
article

Glibenclamide And Cariovascular Risk In Diabetic Patients

article en

Abstract

Glibenclamide (also known as glyburide) is an oral medication used to treat type 2 diabetes. It belongs to a class of drugs called sulfonylureas, which work by stimulating the pancreas to release more insulin, thereby lowering blood glucose levels

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Openalex Percentile: Top 51%
Diabetes Treatment and Management
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Glibenclamide And Cariovascular Risk In Diabetic Patients · Zenodo (CERN European Organization for Nuclear Research) (2024) | TGRS Research Map | TGRS